Nikfar S, et al. - Experts assessed the clinical effectiveness and safety of interleukin-1 receptor antagonist (anakinra) for rheumatoid arthritis treatment. They searched electronic bibliographic databases PubMed, Scopus, and Web of Sciences from inception to November 2017. On ACR20, HAQ, and ESR, anakinra had a significant improvement. After 48 weeks of treatment, the ACR20 response was maintained. Episodes of treatment-related withdrawals were more with anakinra vs placebo. Statistical significance of other parameters was not seen.